Controlled dynamic remodeling of the spliceosome active site enables the first step of splicing

G Gianfranco Martino (Laboratory of Molecular Modelling and Drug Discovery, Istituto Italiano di Tecnologia) J Jacopo Manigrasso (Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research & Development, AstraZeneca) G Giuseppina La Sala (Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research & Development, AstraZeneca) M Marco Marcia (European Molecular Biology Laboratory Grenoble) M Marco De Vivo (Laboratory of Molecular Modeling & Drug Discovery, Istituto Italiano di Tecnologia, Via Enrico Melen 83, 16142 Genoa, Italy)

Abstract

Recent cryoelectron microscopy data have revealed significant conformational rearrangements of the megadalton spliceosome structure during splicing, an essential catalytic process for maturing most human transcripts. However, the molecular trigger of these structural rearrangements for splicing catalysis remains unclear at the atomic level. Here, by analyzing a consistent dataset of multicomponent spliceosome structures, we identified a minimal set of positively charged residues whose dynamic action remodels the spliceosome active site during the first step of splicing. Through equilibrium and enhanced sampling molecular dynamics simulations of multiple splicing intermediates (>2M atoms), we uncover how these residues dynamically operate in coordination with the transient, temporally ordered binding of key spliceosomal proteins (Prp11, Prp8, and Yju2) at the spliceosome core. Our findings reveal a molecular mechanism that ensures precise and timely spliceosome activation, opening promising directions to probe splicing regulation and potentially target its dysfunction in diseases, with broad implications for drug discovery and medicine.

Article Details

Volume / Issue Vol. 123, Issue 1
Published January 06, 2026
ISSN 0027-8424
Publisher National Academy of Sciences

Authors (5)

G

Gianfranco Martino

Laboratory of Molecular Modelling and Drug Discovery, Istituto Italiano di Tecnologia

J

Jacopo Manigrasso

Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research & Development, AstraZeneca

G

Giuseppina La Sala

Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research & Development, AstraZeneca

M

Marco Marcia

European Molecular Biology Laboratory Grenoble

M

Marco De Vivo

Laboratory of Molecular Modeling & Drug Discovery, Istituto Italiano di Tecnologia, Via Enrico Melen 83, 16142 Genoa, Italy